Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652106 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study of Glaucoma and Ocular Hypertension, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 432
- Enrollment target
- 1
- Study location
NCT00652106 is a Phase 3 study of Glaucoma and Ocular Hypertension that has completed, run by Allergan. The registered enrollment target is 432 participants, below the 906-participant average among 92 other Glaucoma trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00652106, a Phase 3 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 432 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the safety and efficacy of brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution compared with concurrent brimonidine 0.2% and timolol ophthalmic solutions
Conditions Studied
Interventions
- DRUG 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
- DRUG Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
- DRUG Brimonidine 0.2% ophthalmic solution
Study Locations (1)
Texas
- - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00652106
The ClinicalTrials.gov registry entry for NCT00652106 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 906-participant average among 92 other Glaucoma trials with a reported enrollment target (52% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution is the first listed.
NCT00652106 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00652106 about?
NCT00652106 is a clinical study titled "Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension". This study evaluates the safety and efficacy of brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution compared with concurrent brimonidine 0.2% and timolol ophthalmic solutions
What is the current status of trial NCT00652106?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 2003-06. Estimated completion is 2004-03.
What conditions does trial NCT00652106 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT00652106?
The interventions under investigation include: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution (DRUG), Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution (DRUG), Brimonidine 0.2% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00652106?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00652106 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilocarpine Use After Kahook Goniotomy
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
COMPLETED · Phase 3
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.